Table 1.
Demographic and clinical data at the time of malaria
| Characteristics | Number |
|---|---|
| Mean age, yr, n=23 | 47 (range, 24–66) |
| Sex, n=23 | |
| Men | 12 (52%) |
| Women | 11 (48%) |
| Race, n=23 | |
| Black | 22 (96%) |
| White | 1 (4%) |
| HIV status, n=23 | |
| Positive | 10 (43%) |
| Mean HIV viral load, copies/ml, n=9/10 | 458,000 (range, undetectable to 2.106) |
| Mean CD4 count, /mm3, n=9/10 | 345 (range, 17–910) |
| Plasmodium species, n=23 | |
| Plasmodium falciparum | 22 (96%) |
| Plasmodium malariae | 1 (4%) |
| Mean parasitemia, %, n=16/23 | 7 (range, 0.3–29) |
| Admission unit, n=23 | |
| ICU | 11 (48%) |
| Malaria severity criteria, n=23 | |
| None | 1 (4.5%) |
| %P | 1 (4.5%) |
| AKI | 15 (64%) |
| Neurologic criteriaa | 1 (4.5%) |
| AKI and %P | 2 (9%) |
| AKI and ARDS | 1 (4.5%) |
| AKI and neurologic criteriaa | 1 (4.5%) |
| AKI, neurologic criteria, and %Pa | 1 (4.5%) |
| Specific treatment of malaria episode, n=22/23 | |
| Quinine | 4 (18%) |
| Artesunate | 10 (45%) |
| Arteminol piperaquine | 4 (18%) |
| Atovaquone proguanil | 2 (9%) |
| Atovaquone proguanil + artesunate | 1 (5%) |
| Atovaquone proguanil + artesunate + quinine | 1 (5%) |
ICU, intensive care unit; %P, parasitemia expressed as a percentage; ARDS, acute respiratory distress syndrome.
a
Neurologic criteria: neurologic involvement including impaired consciousness and/or prostration and/or multiple convulsions.